References

tumors

Malignant tumours

2224-50572587-6813

Rosoncoweb

tumors-279

Research Article

Статьи

МЕТАСТАТИЧЕСКИЙ РАК АНАЛЬНОГО КАНАЛА: ВОЗМОЖНОСТИ ХИМИОТЕРАПИИ И ПЕРСПЕКТИВЫ

Федянин

М. Ю.

Федянин Михаил Юрьевич – кандидат медицинских наук, старший научный сотрудник отделения клинической фармакологии и химиотерапии

fedianinmu@mail.ru

Российский онкологический научный центр имени Н. Н. БлохинаRussian Federation

2016

17112016

04s11419

2016

Федянин М.Ю.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.malignanttumors.org/jour/article/view/279

У 80–95% больных плоскоклеточный рак анального канала диагностируется в виде ранней или местно-распространенной стадии. Метастатическая болезнь выявляется только у 5–15 больных на момент постановки диагноза и 10–20% метастазы разовьются после окончания первичного химиолучевого лечения. В связи с этим, а также редкостью патологии доказательной базы по выбору системной терапии при метастазах рака анального канала в литературе крайне мало.

В данном обзоре литературы мы разберём современные стандарты лечения метастатического плоскоклеточного рака анального канала и результаты исследований последних лет по введению в схемы лечения препаратов нового класса — таргетной терапии и иммунотерапии.

рак анального каналахимиотерапиятаргетная терапияиммунотерапия

References1

Horner M., Ries L., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2006.

Arnott S., Cunningham J., Gallagher J., UK Co-ordinating Committee on Cancer Research Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049-1054.

Cummings B. J. Metastatic anal cancer: the search for cure. Onkologie. 2006;29(1-2):5-6.

https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#anal

Eng C., Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008; 9(4-6):400-407.

James R., Wan S., Glynne-Jones R., et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol. 2009;27(18 suppl). Abstract LBA4009.

Ajani J. A., Carrasco C. H., Jackson D. E., Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87:221-224.

Pathak P., King B., Ohinata A., et al. The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: a single institution experience [abstract]. J Clin Oncol. 2008; 26(15 suppl). Abstract A352.

Faivre C., Rougier P., Ducreux M., et al. 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer [article in French]. Bull Cancer. 1999;86:861–865.

Bosset J. F., Roelofsen F., Morgan D. A., et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer. 2003; 39:45–51.

Eng C., Chang G., Das P., et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOXXRT) for squamous cell carcinoma of the anal canal [abstract].J Clin Oncol. 2009;27:15(suppl). Abstract 4116.

Blazy A., Hennequin C., Gornet J. M., et al: Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2005;48:1176–1181.

Kim R., Byer J., Fulp W. J., et al. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014;87: 125–132.

Alcindor T. Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Colorectal Dis. 2008; 23:717.

Abbas A., Nehme E., Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res. 2011;31:4637–4640.

Kim S., Jary M., Mansi L., et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013; 24:3045–3050.

Hainsworth J. D., Burris H.A 3rd, Meluch A. A., et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas.Cancer. 2001;92:642–649.

Byer J., Mahipal A., Dinwoodie W. R., et al. Efficacy of carboplatin and paclitaxel therapy in patients with advanced squamous cell carcinoma (SCC) of the anal canal. J Clin Oncol. 2013; 31(suppl 4; abstr 539).

Golub D. V., Civelek A. C., Sharma V. R. A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract. 2011; 2011: ID163736.

Cacheux W., Lievre A., De La Rochefordiere A., et al. Chemotherapy in the treatment of anal canal carcinoma. Dig Liver Dis. 2012 Oct;44(10):803–11.

Greenall M. J., Magill G. B., Quan S. H. Q. and DeCosse J. J. Recurrent epidermoid cancer of the anus. Cancer. 1986; vol.57, no.7:1437–1441.

Wilking N., Petrelli N., Herrera L., et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemotherapy and Pharmacology 1985; 15:300–2.

Jhawer M., Mani S., Lefkopoulou M., et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investigational New Drugs 2006;24:447–54.

Magill G. B., Quan S. Salvage chemotherapy of anal epidermoid carcinoma with cisplatin based protocols. Proc Am Soc Clin Oncol. 1989; 8:117(abstr 456).

Eng C, Chang G. J., You Y. N., et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov; 5(22): 11133–11142.

Clinicaltrials.gov. (2014). International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT).

Boland P. M.K., Wang K., Kohen A. Systemic therapy for advanced anorectal squamous cell carcinomas: A single institutional experience. J Clin Oncol. 2016;34(suppl 4S; abstr 728).

Paliga A., Onerheim R., Gologan A., et al. EGFR expression in invasive anal carcinoma. Journal of Clinical Oncology. 2011; vol.29, no.4: suppl., abstr. 412.

Van Damme N., Deron P., Van Roy N., et al. Epidermal growth factor receptor and KRAS status in two cohorts of squamous cell carcinomas [serial online]. BMC Cancer. 2010;10:189.

Gardini A. C., Capelli L., Ulivi P., et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One. 2014;9: e92071.

Bidinotto L. T., V o C. A., Loaiza E. A., et al. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors. Mol Med Rep. 2016 Aug 26. doi: 10.3892/mmr.2016.5684. [Epub ahead of print].

Olivatto L. O., Vieira F. M., Pereira B. V., et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119:2973–2980.

Deutsch E., Lemanski C., Paris E., et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: interim results of the French multicenter phase II trial ACCORD16 [abstract]. J Clin Oncol. 2011;29(7 suppl). Abstract 4098.

Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer. 2003; 39:45–51.

http://www.ffcd.fr

Feliu J., Garcia-Carbonero R., Capdevila J., et al. Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile — VITAL study, GEMCAD09–02 clinical trial. J Clin Oncol. 2014;32:5s(suppl; abstr 4034).

Saif M. W., Kontny E., Syrigos K. N., et al. The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. Journal of Oncology. J Oncol. 2011;2011: 125467.

Lukan N., Str bel P., Willer A., et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009; 77:293–9.

Phan L. K., Hoff P. M. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Diseases of the Colon and Rectum. 2007;50:395–8.

De Dosso S., Martin V., Zanellato E., et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010: vol.96, no.4:627–628.

Barmettler H., Komminoth P., Schmid M., Duerr D. Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. Case Rep Oncol. 2012; 5:428–433.

Bamba T., Suda T., Nakano M., et al. Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab — a case report. Gan To Kagaku Ryoho.2012; 39:311–315.

Matsunaga M., Miwa K., Oka Y. Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab. Case Rep Oncol. 2016 Apr 26;9(1):249–54.

Patel H., Polanco-Echeverry G., Segditsas S., et al. Signaling. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous-cell carcinoma. Int J Cancer 2007; 121(12):2668–73.

Oh K. J., Kalinina A., Park N. H., Bagchi S. Deregulation of eIF4E; 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. J Vitol 2006; 80(14):7079–88.

Cacheux W., Rouleau E., Tsantoulis P., et al. PI3KCA mutation as an independent pronostic factor in anal squamous cell carcinoma treated by abdomino-perineal resection: Evidence from a retrospective cohort of 148 patients. J Clin Oncol. 2016; 34(suppl; abstr e15060).

Burris H. A., Siu L. L., Infante J. R., et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol. 2011; 29(suppl; abstr 3003).

Hyman D. M., Tran B., Jaime J. C., et al. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. J Clin Oncol. 2016; 34(suppl; abstr 2500).

Mita M. M., Tolcher A., Gordon M. S., et al. A phase Ib dose- escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients. J Clin Oncol. 2009; 27(suppl; abstr e13511).

Hamilton E. P., Wang S. Z.J., Falchook G., et al. A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. J Clin Oncol. 2016; 34(suppl; abstr 5562).

Lin C., Ghamande S. A., Dezube B. J., et al. TLC388, a novel topoisomerase-1 inhibitor with antihypoxia inducible factor-1 alpha activity: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 28, 2010 (suppl; abstr e13020).

Jonker D. J., Stephenson J., Edenfield W. J., et al. A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 2546).

Clancy M. S., Cleary J. M., Mani S., et al. Novel tubulin inhibitor ALB109564(a) in patients with solid tumors: A phase I trial. J Clin Oncol. 2010; 28(suppl; abstr e13119).

Duxbury M. S., Ito H., Zinner M. J., et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10:2307–2318.

Park S. I., Zhang J., Phillips K. A., et al. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68:3323–3333.

Hong D. S., Choe J. H., Naing A., et al. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 August;31(4): 918–926.

fda.gov

Morris vav K., Ciombor K. K., Salem M. E., et al. NCI9673: a multi- institutional eETCTN phase II study on nivolumab in refractiory metastatic squamous cell carcinoma of the anal canal (SCCA). J Clin Oncol 34, 2016 (suppl; abstr 3503).

Ott P. A., Piha-Paul S.A., Munster P., et al. Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. European Journal of Cancer, 2015; Vol.51, Suppl.3: S102.

The authors declare that there are no conflicts of interest present.